gemcitabine + cisplatin + trastuzumab + pembrolizumab

This combination therapy regimen, often referred to as GemCis plus trastuzumab and pembrolizumab, is a quadruplet therapy being investigated as a first-line treatment for HER2-positive, unresectable biliary tract cancers, including cholangiocarcinoma and gallbladder cancer. It combines the standard-of-care chemotherapy doublet (gemcitabine and cisplatin) with the HER2-targeted monoclonal antibody trastuzumab and the PD-1 immune checkpoint inhibitor pembrolizumab. The regimen aims to leverage the synergistic effects of cytotoxic chemotherapy, targeted HER2 inhibition, and immune checkpoint blockade to improve clinical outcomes in this specific patient population. The trial is sponsored by the Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest and is based on the rationale that adding immune checkpoint inhibitors to HER2-directed therapy can stimulate HER2-specific immune responses and overcome resistance mechanisms.

Other names

GemCis + trastuzumab + pembrolizumabSOC plus trastuzumab and pembrolizumabtrastuzumab + pembrolizumab-Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest-cholangiocarcinoma-gallbladder cancer